March 29 (Reuters) - Abeona Therapeutics Inc ABEO.O :
* ABEONA THERAPEUTICS REPORTS FULL YEAR 2022 FINANCIAL
RESULTS AND
PROVIDES CORPORATE UPDATE
* ABEONA THERAPEUTIC -EXPECTS TO SUBMIT BLA FOR EB-101 TO
FDA IN
LATE-2Q/EARLY-3Q 2023
* ABEONA THERAPEUTICS INC - CASH, CASH EQUIVALENTS,
RESTRICTED
CASH AND SHORT-TERM INVESTMENTS TOTALED $52.5 MILLION AS OF
DECEMBER 31, 2022
* ABEONA THERAPEUTICS INC - FY 2022 LOSS PER COMMON SHARE
$5.53
Source text for Eikon: ID:nGNX7XPxPd
Further company coverage: ABEO.O
((Reuters.Briefs@thomsonreuters.com;))